Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Challenge Dose of Twinrix vs Comparators 4 Years Post-Primary Vaccination
NCT00684671Phase 4Completed
- Sponsor
- GSK
- Start
- May 2008
- Primary completion
- Nov 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of hepatitis b vaccine recombinant in hepatitis A (HAV) and hepatitis B (HBV) (3 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Anamnestic Response to the Challenge Dose for Anti-hepatitis A (Anti-HAV) Antibodies at 1 month and Number of Subjects With Anamnestic Response to the Challenge Dose for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies at 1 month. Started May 2008; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00684671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684671.